Primary Immunodeficiencies - Epidemiology, Spending on Therapy, Diagnostic and Therapeutic Needs in Poland

• Autorzy: Karina Jahnz-Różyk , Maciej Siedlar , Ewa Bernatowska , Jacek Roliński , Magorzata Pac , Ewa Więsik-Szewczyk , Magdalena Dylewska , Sylwia Żmiejko , Magdalena Mikułowska , Bogdan Falkiewicz
• Języki publikacji: EN

Abstrakty

EN

Primary immunodeficiencies (PID) are a heterogeneous group of over 300 diseases of the immune system characterised by its disfunction, and in consequence by chronic or recurrent infections, autoimmunity, allergy, neoplastic diseases or autoinflammation (1). One of the key problems at the international level is low awareness of symptoms and course of primary immunodeficiency. Based on the epidemiological data on the disease incidence, it can be estimated that ca. 70-80% of PID cases have still not been diagnosed (2). The main issue on the country level is the lack of large scale analyses concerning the actual number of PID patients in Poland, which limits the potential to streamline the disease diagnostic and therapeutic process. The following paper is an attempt to prepare a synthetic summary of epidemiological data and main problems related to PID diagnostics and therapy in Poland and to present the costs of reimbursed healthcare services related to this group of patients.(original abstract)

Słowa kluczowe

EN

Medical treatment; Illness; Expenditures on health care

PL

Leczenie; Choroby; Wydatki na ochronę zdrowia

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2017
• Numer: nr 1
• Strony: 21--34

Twórcy

autor

Karina Jahnz-Różyk

• Military Institute of Medicine, Warsaw, Poland

autor

Maciej Siedlar

• Jagiellonian University Medical College, and University Children's Hospital

autor

Ewa Bernatowska

• Children's Memorial Health Institute

autor

Jacek Roliński

• Center of Oncology in Lublin

autor

Magorzata Pac

• Children's Memorial Health Institute

autor

Ewa Więsik-Szewczyk

• Military Institute of Medicine in Warsaw

autor

Magdalena Dylewska

• PEX PharmaSequence Team

autor

Sylwia Żmiejko

• PEX PharmaSequence Team

autor

Magdalena Mikułowska

• PEX PharmaSequence Team

autor

Bogdan Falkiewicz

• PEX PharmaSequence Team

Bibliografia

• Bousfiha, A.; Jeddane, L.; Al-Herz, W.; et al. The 2015 IUIS Phenotypic Calssification for Primary Immunodeficiencies. J Clin Immunol. 2015, 35: 727- 38.
• International Patient Organisation for Primary Immodeficiencies (IPOPI). Facts about PID for Governments. http://www.ipopi.org/uploads/ Governments Guidelines.pdf. [Online] [Cited: 20 August 2016.]
• Brzustewicz, E.; Bryl, E. Przegląd testów laboratoryjnych przydatnych w diagnostyce pierwotnych niedoborów odporności. Forum Med Rodz. 2014, 8: 27-36.
• HTA Consulting (for: The Agency for Health Technology Assessment and Tariff System (AOTMiT)). HyQvia's budgetary impact analysis and rationalization analysis for the treatment of primary immunodeficiency in adults. http://www.aotm.gov. pl/bip/assets/files/zlecenia_mz/2015/020/AW/020_ AW_3_BOR_4351_1_BIA_PNO_HyQvia_20150409. pdf. [Online] 2015. [Cited: 11 August 2016.]
• Modell, V.; Knaus, M.; et al. Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment and discovery. Immunol Res. 2014, 60: 132.
• Bousfiha, A.; Jeddane, L.; Ailal, L. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol. 2013, 33: 1. doi:10.1007/s10875-012-9751-7.
• Pac, M.; Bernatowska, E. Comperhensive activities to increase recognition of promary immunodeficiency and access to immunoglobulin replacement therapy in Poland. Eur J Pediatr. 2016, 175: 1099-105.
• Mahlaoui, N.; Gathmann, B.; et al. The European Society for Immunodeficiencies (ESID).Registry: Recent advancements in the epidemiology of Primary Immunodeficiencies and how does that translate in clinical care. Int J Public Health. 2014, 4: 26-27.
• Statistical Information of the Supreme Medical Council - Number of clinical immunologists. http:// www.nil.org.pl/rejestry/centralny-rejestr-lekarzy/ informacje-statystyczne. [Online] [Cited: 09 January 2017.]
• National Health Found (NHF). Time information on medical benefits. http://kolejki.nfz.gov.pl/Informator/ Index/. [Online] [Cited: 08 August 2017.]
• Public Information Bulletin of the Ministry of Health. Map of health needs in hospital care in Poland. http://www.bip.mz.gov.pl/ogloszenia/mapy-potrzebzdrowotnych/. [Online] [Cited: 19 August 2017.]
• Institute of Paediatrics, Jagiellonian University Medical College, and University Children's Hospital, Data on genetic research at the University Children's Hospital in Cracow. Cracow, 2016.
• Social Insurance Institution (ZUS). Absenteeism in 2015. Department of Statistics and Actuarial Forecasts, 2015.
• PEX PharmaSequence: Dylewska, M.; Żmiejko, S.; Mikułowska, M.; Falkiewicz, B. Pierwotne Niedobory Odporności - Stan obecny oraz potrzeby diagnostyki i terapii w Polsce." PEX PharmaSequence, Warszawa, 2017.
• Mikułowska, M.; Kiełczewski, T.; Majda, M.; Jarosz, A.; Cudny M. Terminy w programach lekowych. Sequence HC Partners, Warszawa, 2015.
• HTA Consulting for: The Agency for Health Technology Assessment and Tariff System (AOTMiT). Clinical analysis of HyQvia for the treatment of primary immunodeficiencies. http://bipold.aotm.gov. pl/assets/files/zlecenia_mz/2015/020/AW/020_AW_1_ BOR_4351_1_AK_HyQvia_20150409.pdf. [Online] [Cited: 10 September 2016.]
• National Health Found (NHF). Data on NHF contracts concluded by NHF regional departments in the scope of PIDs treatment. https://aplikacje.nfz.gov. pl/umowy/. [Online] [Cited: 09 August 2017.]
• National Health Found (NHF). Data obtained on the request: Costs of PIDs treatment in Poland. 2016.

Identyfikatory

DOI

10.7365/JHPOR.2017.1.3